The development of the forebrain in homozygous extra-toes mutants (Xt/Xt) was examined histologically from day 11.5 to day 16.5 of gestation. It is shown that until day 16.5 of gestation, the forebrains of Xt/Xt mutant embryos develop neither an olfactory bulb nor a choroid plexus in the lateral ventricles, and do not exhibit lamination in the cerebral cortex. Glial fibrillary acidic protein (GFAP)-expressing glial cells are detected in the prospective cerebral cortex of Xt/Xt animals, indicating that differentiation to glial cells is not disturbed. Upon comparison with a Splotch mutant, it is demonstrated that delayed closure of the anterior neuropore cannot account for the extra-toes specific defect in the developing cerebral cortex. It is, therefore, suggested that the forebrain phenotype in Xt/Xt mutant embryos is caused by the direct action of the mutation on the forebrain. As the zinc finger gene Gli-3 is deleted in extra-toes mutants, these observations suggest that the proper expression of the Gli-3 gene in the forebrain is a prerequisite for the normal development of the telencephalon and later of the cerebral cortex.

Keywords:
Brain, Embryology, Gli-3 gene, Extra toes, Mutant, Mouse
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.